TY - JOUR T1 - Real World SOF/VEL/VOX Retreatment Outcomes and Viral Resistance Analysis for HCV Patients with Prior Failure to DAAs JF - medRxiv DO - 10.1101/2020.10.13.20211862 SP - 2020.10.13.20211862 AU - David A Smith AU - Daniel Bradshaw AU - Jean Mbisa AU - Carmen F Manso AU - David Bibby AU - Josh Singer AU - Emma Thomson AU - Ana Filipe AU - Elihu Aranday-Cortes AU - M. Azim Ansari AU - Anthony Brown AU - Emma Hudson AU - Jennifer Benselin AU - Brendan Healy AU - Phil Troke AU - STOP-HCV Consortium AU - HCV Research UK AU - John McLauchlan AU - Eleanor Barnes AU - William L Irving Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/14/2020.10.13.20211862.abstract N2 - Sustained viral response (SVR) rates to first-line Direct Acting Antiviral (DAA) therapy for hepatitis C virus (HCV) infection routinely exceed 95%. However, a small number of patients require retreatment. Sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is a potent DAA combination primarily used for the retreatment of patients failed by first line DAA therapies. Here we evaluate retreatment outcomes and the effects of resistance associated substitutions (RAS) in a real-world cohort, including the largest number of genotype (GT)3 infected patients, to date. 144 patients from the UK were retreated with SOF/VEL/VOX following virologic failure with first-line DAA treatment regimens. Full-length HCV genome, next-generation sequencing was performed prior to retreatment with SOF/VEL/VOX. HCV subtypes were assigned and RAS relevant to each genotype were identified (15% read cut-off). GT1a and GT3a were the two most common subtypes in the cohort, each making up 38% (GT1a n=55, GT3a n=54) of the cohort. 40% (n=58) of patients had liver cirrhosis of whom 7% (n=4) were decompensated, 10% (n=14) had hepatocellular carcinoma (HCC) and 8% (n=12) had received a liver transplant prior to retreatment. The overall re-treatment SVR12 rate was 90% (129/144). On univariate analysis, GT3 infection (50/62; SVR=81%, p=0.009), cirrhosis (47/58; SVR=81%, p=0.01) and prior treatment with SOF/VEL(12/17; SVR=71%, p=0.02) or SOF + DCV (14/19; SVR=74%, p=0.012) were all significantly associated with retreatment failure, but existence of pre retreatment RAS was not when the genotype of the virus is taken into account. The lower SVR rates achieved in patients retreated with SOF/VEL/VOX for patients with GT3 infection, cirrhosis and prior treatment with SOF/VEL or SOF/DCV has important implications for both patients and HCV elimination strategies.Competing Interest StatementDB has received a research grant from Gilead. WLI has received speaker and consultancy fees from Roche, Janssen Cilag, Gilead Sciences and Novartis, educational grants from Boehringer Ingelheim, Merck Sharp and Dohme and Gilead Sciences, and research grant support from GlaxoSmithKline, Pfizer, Gilead Sciences, Janssen Cilag, Abbvie and Bristol-Myers Squibb. The remaining authors have no conflicts of interest.Funding StatementThis work was supported by an Investigator-Sponsored Research Grant IN-UK-342-4409 Real world assessment of retreatment of patients who have failed initial DAA therapy in the UK from Gilead Sciences Ltd. DAS is funded by the Oxford NIHR Biomedical Research Centre..JM was funded by the UK Medical Research Council (MC_UU_12014/1). DB is funded by Public Health England. CM is funded by Public Health England. EB is/was funded by the Medical Research Council UK, the Oxford NIHR Biomedical Research Centre and is an NIHR Senior Investigator. The views expressed in this article are those of the author and not necessarily those of the NHS, the NIHR, or the Department of HealthAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethicaly approval for data from HCV Research UK was provided by NHS Research Ethics Committee. Approval for the use of data from Public Health England antiviral resisitance service was granted under Regulation 3 of the Health Service (Control of Patient Information) Regulations 2002All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData can be made avalible on requast.SVRSustained Viral ResponseHCVHepatitis C VirusDAADirect Acting AntiviralRASResistance Associated SubstitutionNSNon-StructuralSOFSofosbuvirLDVLedipasvirVELVelpatasvirGLEGlecaprevirPIBPibrentasvirEASLEuropean Association for the Study of the LiverAASLDAmerican Association for the Study of Liver DiseaseVOXVoxilaprevirGTGenotypeHCCHepatocellular CarcinomaDCVDaclatasvirRBVRibavirinPHEPublic Health EnglandWGSWhole Genome SequencingGLUEGenes Linked by Underlying Evolution ER -